Early testing getty

A new blood test capable of detecting more than 50 types of cancer has delivered highly promising results in one of the largest interventional screening trials to date. The PATHFINDER 2 study of the Galleri multi-cancer early detection (MCED) test showed a more than seven-fold increase in cancer detection rates when added to standard recommended screenings.

Major Breakthrough in Cancer Screening

Results presented at the Eur opean Society for Medical Oncology Congress 2025 in Berlin revealed that more than half of the cancers detected were at an early stage (stage I or II), when they are most treatable. Approximately three-quarters of the cancers detected have no existing standard screening program—such as pancreatic, liver, ovarian, and stomach canc

See Full Page